- CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 - - Phase 1 clinical study of CX-2051, an EpCAM targeting PROBODY ® ADC, is ongoing. Study is currently enrolling third cohort with

SOUTH SAN FRANCISCO, Calif. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report second quarter financial results on Thursday, August 8, 2024 , after the

SOUTH SAN FRANCISCO, Calif. , June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy , D.Phil ., chief executive officer and chairman, will participate in a

SOUTH SAN FRANCISCO, Calif. , June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024 .

SOUTH SAN FRANCISCO, Calif. , May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy , D.Phil ., chief executive officer and chairman, will present at the Jefferies

SOUTH SAN FRANCISCO, Calif. , May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024 , the Company granted two new employees options to purchase a total of 130,000 shares of

- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY ® ADC, in solid tumors. Initial data anticipated in the first half of

- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial signs of efficacy observed for CX-904 in advanced pancreatic cancer, including 2 of 6 patients (33%)

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform -                    - Phase 1 first-in-human study expected to start in first half of 2024 - - Clinical trial will evaluate CX-801 as monotherapy and in combination with

- CX-904 (masked EGFRxCD3 Probody ® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study - - Management to hold conference call at 5 p.m. EDT / 2 p.m. PDT on May 8 th - SOUTH SAN FRANCISCO, Calif. , May 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics,